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Abstract
Background: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations that
activate the PI3K/AKT signaling pathway have been observed in several types of carcinoma and have been
associated with patient prognosis. However, the significance of PIK3CA mutations in gastric cancer remains unclear.
This retrospective study investigated the relationship between PIK3CA mutations and clinical outcomes in patients
with gastric cancer. Additionally, we reviewed the rate of PIK3CA mutations in gastric cancer and the association
between PIK3CA mutations and prognosis in human cancers.
Methods: The study included 208 patients with gastric cancer who underwent surgical resection at Kumamoto
University Hospital, Japan, between January 2001 and August 2010. Mutations in PIK3CA exons 9 and 20 were
quantified by pyrosequencing assays.
Results: PIK3CA mutations were detected in 25 (12 %) of the 208 patients. Ten patients had c.1634A > G (p.E545G), 10
had c.1624G > A (p.E542K), 13 had c.1633G > A (p.E545K), nine had c.3139C > T (p.H1047R), and 1 had c.3140A > G (p.
H1047Y) mutations. PIK3CA mutations were not significantly associated with any clinical, epidemiologic, or pathologic
characteristic. Kaplan–Meier analysis showed no significant differences in disease-free survival (log rank P = 0.84) and
overall survival (log rank P = 0.74) between patients with and without PIK3CA mutations.
Conclusions: Mutations in PIK3CA did not correlate with prognosis in patients with gastric cancer, providing additional
evidence for the lack of relationship between the two.
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Background
Gastric cancer is the third leading cause of cancer deaths
in the world, with 723,000 patients dying of gastric
cancer in 2012 [1]. Elucidating the biological pathways
leading to the development of gastric carcinoma is
crucial because accumulation of genetic alterations has
been shown to result in tumor development [2]. Genetic
alterations involving proteins along several signaling
pathways, such as the constitutive activation of receptor
tyrosine kinases and G-protein-coupled receptors, and
GTP-binding proteins to adaptor proteins, could lead to
activation of the phosphoinositide 3-kinase (PI3K)-AKT
pathway [3–6]. As PI3K signaling plays essential roles in
cell growth, metabolism, survival, metastasis, and resist-
ance to chemotherapy, the PI3K-AKT pathway has been
considered extremely important in the carcinogenic
process [7–10].
Mutations in the phosphatidylinositol-4,5-bispho-
sphate 3-kinase, catalytic subunit alpha (PIK3CA)
gene, which encodes the p110 catalytic subunit of
PI3K, have been found in several types of carcinoma
[11, 12]. The hot spots of PIK3CA mutations have
been located at five sites in exons 9 and 20 [13].
These mutations activate the PI3K/AKT signaling
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pathway, activating downstream signaling pathways,
and thereby contribute to carcinogenesis [13].
PIK3CA mutations in several types of human cancer
have been associated with patient prognosis. However
the impact of PIK3CA mutations on prognosis varies
among tumor types [14].
The significance of PIK3CA mutations in gastric
cancer remains unclear. Although several reports have
Fig. 1 PIK3CA exon 9 and exon 20 pyrograms (antisense strand). a Wild-type exon 9 sequenced with the 9-RS1 primer and the c.1634A > G
mutation (arrow), causing a shift in the reading frame and a new peak at A (arrowhead), which serves as quality assurance. b Wild-type exon 9
sequenced with the 9-RS2 primer and the c.1624G > A mutation (arrow), causing a shift in the reading frame and a new peak at A (arrowhead).
c Wild-type exon 9 sequenced with the 9-RS3 primer and the c.1633G > A mutation (arrow), causing a shift in the reading frame and new peaks
(arrowheads). d Wild-type exon 20 sequenced with the exon 20 primer and the c.3139C > T mutation (arrow), causing a shift in the reading frame
and a new peak at T (arrowhead). Wild-type exon 20 sequenced with the exon 20 primer and the c.3140A > G mutation (arrow), causing a shift in
the reading frame and a new peak at G (arrowhead). Mut, mutant; WT, wild-type
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shown a relationship between PIK3CA mutations and
prognosis, relative few patients were analyzed and
findings differ among studies. This study used pyrose-
quencing to evaluate PIK3CA mutations in patients with
gastric cancer at our hospital, as well as determining the
relationship between PIK3CA mutations and patient
prognosis. Additionally, we reviewed the rate of PIK3CA
mutations in gastric cancer and the association between
PIK3CA mutations and prognosis in human cancers.
Methods
Study subjects
This study retrospectively enrolled 208 gastric cancer
patients who underwent resection at Kumamoto
University Hospital between January 2001 and August
2010. Patients who underwent palliative resection and/or
whose tissue samples were unavailable were excluded,
but patients positive on peritoneal washing cytology
were included. Patients were followed-up at 1- to 3-
Table 1 PIK3CA mutational status and clinical features in gastric cancers
Features Total PIK3CA mutation p value
Mutant Wild-Type
n = 208 n = 25 (12 %) n = 183 (88 %)
Age (year) 0.30
Mean ± SE 208 67.4 ± 2.1 69.8 ± 0.8
Sex 0.41
Male 148 16 (11) 132 (89)
Female 60 9 (15) 51 (85)
Location 0.22
Upper 75 13 (17) 62 (83)
Middle 65 6 (9) 59 (91)
Lower 68 6 (9) 62 (91)
Tumor depth 0.09
T1 105 18 (17) 87 (83)
T2 29 2 (6) 29 (94)
T3 42 2 (5) 42 (95)
T4 25 3 (11) 25 (89)
Lymph node involvement 0.73
Absent 135 17 (13) 118 (87)
Present 73 8 (11) 65 (83)
Stage 0.78
I 123 17 (14) 106 (86)
II 40 4 (10) 36 (90)
III 26 2 (8) 24 (92)
IV 19 2 (11) 17 (89)
Lauren classification 0.79
Intestinal 138 16 (12) 122 (88)
Diffuse 70 9 (13) 61 (87)
Venous invasion 0.05
Absent 111 18 (16) 93 (84)
Present 95 7 (7) 88 (93)
Lymphatic invasion 0.40
Absent 117 16 (14) 101 (86)
Present 91 9 (10) 82 (90)
LINE-1 methylation level (%) 0.19
Mean ± SE 208 74.9 ± 2.6 71.2 ± 1.0
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, LINE-1 long interspersed nucleotide element-1, SE standard error
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month intervals until death or 31 March 2015, which-
ever came first. Disease-free survival was defined as the
time from the date of surgery to the date of cancer
recurrence or death. Tumors were staged according to
the American Joint Committee on Cancer Staging
Manual (7th edition) [15]. Overall survival was defined
as the time from the date of the operation to the date of
death. All procedures followed were in accordance with
the ethical standards of the responsible committee on
human experimentation (institutional and national) and
with the Helsinki Declaration of 1964 and later versions.
Informed consent or substitute for it was obtained from
all patients for being included in the study. The study
procedures were approved by the Ethics Committee for
Epidemiological and General Research at the Faculty of
life Science, Kumamoto University (Approval number:
Ethic 559). Throughout this article, the definition of
“prognostic marker” is consistent with REMARK Guide-
lines [16].
Genomic DNA extraction
Genomic DNA was extracted from paraffin-embedded
tissue specimens of surgically resected gastric cancers.
Tumors areas were marked on hematoxylin and eosin
stained slides by one pathologist (Y. Baba). Genomic
DNA was extracted from tumor lesions enriched with
neoplastic cells, without adjacent normal tissue, using
FFPE Kits (Qiagen, Duesseldorf, Germany).
Pyrosequencing for PIK3CA mutations
PIK3CA mutations were evaluated as previously described
[14]. The exon 9 PCR primers were 5′-biotin-AACAGCTC
AAAGCAATTTCTACACG-3′ (forward, PIK3CA 9-F) and
5′-ACCTGTGACTCCATAGAAAATCTTT-3′ (reverse,
PIK3CA9-R). The exon 20 PCR primers were 5′-biotin-
CAAGAGGCTTTGGAGTATTTCA-3′ (forward, PIK3CA
20-F) and 5′-CAATCCATTTTTGTTGTCCA-3′ (reverse,
PIK3CA 20-R). In the PIK3CA exon 9 pyrosequencing as-
says, the presence of mutations was routinely confirmed
using three different sequencing primers and by the cre-
ation of a frameshifted reading of a mutant sequence
relative to a wild-type sequence. The primers PIK3CA
9-RS1 (5′-CCATAGAAAATCTTTCTCCT-3′; nucleo-




TAGCTAGCTAGCTAG) and PIK3CA 9-RS3 (5′-
TAGAAAATCTTTCTCCTGCT-3′; nucleotide dispen-
sation order, ATAGCACTGACTGACTGACTACT-
GACTGACTGACTG) could detectc.1634A > G, c.1624
A > G, and c.1624G > A mutations, respectively. For
PIK3CA exon 20, the primer PIK3CA 20-RS (5′-
GTTGTCCAGCCACCA-3′; nucleotide dispensation
order, CTGACGATACTGTGCATCATATGCATGCAT
GCATGCATGC) was used to detect the mutations
c.3140A > G and c.3139C > T. Nucleotide dispensation
orders were designed so that if any of the common
mutations were present, it caused a shift in the
reading frame and resulted in an additional peak or
peaks following the mutated nucleotide. Representa-
tive pyrograms of wild-type and mutant exons 9 and
20 are shown in Fig. 1.
Statistical methods
The results were statistically analyzed by JMP software
(Version 9, SAS Institute, Cary, NC, USA). All p-values
were two-sided. The means were compared by t test,
Fig. 2 Kaplan–Meier curves showing the relationship of PIK3CA mutational status with overall survival (left) and disease-free survival (right) in
gastric cancer patients
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assuming unequal variances. The proportional differ-
ences among the characteristics were evaluated by
Pearson’s chi-squared test (χ2). Survival time was deter-
mined by the Kaplan–Meier method and compared
using the log-rank test. The hazard ratio for PIK3CA
mutations on mortality was assessed by Cox regression
modeling. To assess whether any of these variables was
associated with the relationship between the PIK3CA
mutations and prognosis, they were cross-multiplied
with PIK3CA mutations and subjected to the Wald test.
Results
PIK3CA mutational status in gastric cancer
Of the 208 patients who had undergone curative
resection of gastric cancer, 25 (12 %) were found pyrose-
quencing technology to have PIK3CA exon 9 and 20
mutations (Fig. 1). Ten patients were positive for
c.1634A > G (p.E545G), 10 for c.1624G > A (p.E542K),
13 for c. c.1633G > A (p.E545K), nine for c. 3139C > T
(p.H1047R), and one for c. 3140A > G (p.H1047Y) muta-
tions. Three tumors were positive for mutations at all
three nucleotides in exon 9, three were positive for
mutations at two nucleotides in exon 9. Fifteen samples
were positive for mutations in exon 9 alone, four for
mutations in exon 20 alone, and six were positive for
mutations in both exons.
PIK3CA mutations and patient characteristics
PIK3CA mutations were not significantly associated with
any clinical, epidemiologic, or pathologic characteristic
(Table 1). We previously reported that the long inter-
spersed nucleotide element-1 (LINE-1) methylation level
in gastric cancer was a surrogate marker of global DNA
methylation and genome instability [17, 18]. However,
LINE-1 methylation level was not associated with
PIK3CA mutations (Table 1).
PIK3CA mutations and patient survival
We assessed the influence of PIK3CA mutations on
clinical outcome in patients with curatively resected
Fig. 3 PIK3CA mutations and overall survival in various strata. The
loge (adjusted HRs) plot of overall survival in the PIK3CA mutation vs.
PIK3CA wild-type group. The 95 % CI is also shown
Table 2 Previous studies of PIK3CA mutations in gastric cancer
Sample number Mutation rate Exons evaluated Method References
163 5.5 % 9 and 20 Direct sequencing [36]
263 16 % 9 and 20 Direct sequencing [27]
12 25 % 18 and 20 Sanger method [6]
47 11 % 9 and 20 ABI prism 377 automated sequencer [37]
94 4.3 % 9 and 20 Direct sequencing [38]
185 6.5 % 9, 18 and 20 PCR – SSCP [39]
34 6.0 % 9 and 20 High-Resolution [40]
Melt Analysis
295 24 % All exon Mut Sig CV [41]
140 4.0 % 9 and 20 ABI PRISM 3100 [42]
Genetic Analyzer
231 8.7 % 1, 9 and 20 Pyrosequencing [26]
104 7.7 % 9 and 20 Direct sequencing [28]
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gastric cancer. During follow-up of the 208 patients, 32
patients experienced gastric cancer recurrence and 69
died. The median follow-up time for censored patients
was 5.0 years. Kaplan–Meier analysis showed no
significant differences in disease-free survival (log rank
P = 0.84) and overall survival (log rank P = 0.74) between
patients with PIK3CA mutations and those with
PIK3CA wild type (Fig. 2).
Interaction between PIK3CA mutations and other
variables in survival analyses
We also examined whether the influence of PIK3CA
mutations on overall survival was modified by any
clinical or pathological variable. All tested variables did
not significantly interact with the relationship between
PIK3CA mutations and overall survival (p for all interac-
tions >0.05, Fig. 3). Moreover, analysis of various strata
showed no significant difference in hazard ratio for
overall survival between patients with PIK3CA muta-
tions and those with PIK3CA wild type (Fig. 3).
Discussion
PIK3CA mutations and subsequent activation of the
PI3K/AKT pathway play an essential role in cancer cell
signaling pathways, involving growth factors, cytokines,
and other cellular stimuli associated with human
Table 3 Studies on prognostic significance of PIK3CA mutations in several types of cancers
Cancer type Sample number Mutation rate (%) Mutation effect Prognosis References
Colon cancer 1212 16 Unfavorable Adjusted CS HR [31]
3.51 (1.28–9.62)
743 14.5 Unfavorable Adjusted OS HR [25]
3.30 (1.46–7.45)
450 18 Unfavorable Adjusted CS HR [29]
2.03 (1.15–3.57)
Rectal cancer 240 7.9 Unfavorable Adjusted RS HR [32]
3.4 (1.2–9.2)
Endometrial cancer 1063 16.2 Unfavorable Not-adjusted RS HR [33]
2.18 (1.09–4.39)
Breast cancer 687 25.3 favorable Not-adjusted CS HR [34]
0.88 (0.58–1.34)
439 32.5 Not significant Adjusted CS HR [30]
0.7 (0.4–1.2)
188 28.7 favorable Adjusted RS HR [35]
0.42 (0.20–0.92)
Esophageal cancer 406 7.4 Not significant Adjusted OS HR [43]
1.072 (0.79–1.44)
219 21 favorable Adjusted OS HR [14]
0.35 (0.10–0.90)
Lung cancer 1117 3.4 Not significant OS log-lank [44]
P = 0.442
235 3.4 Not significant OS log-lank [45]
P = 0.15
Gastric cancer 263 15.9 Not significant Adjusted OS HR [27]
1.1 (0.7–1.7)
231 8.7 Not significant Not-adjusted OS HR [26]
1.37 (0.68–3.26)
104 7.7 Not significant OS log-lank [28]
P = 0.96
208 12 Not significant Not-adjusted OS HR This study
0.73 (0.58–2.57)
HR hasard ratio, CS cancer specific survival, RS recurrence-free survival rate, OS overall survival rate
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neoplasms [11, 12, 19, 20]. This study examined the
prognostic impact of PIK3CA mutations on survival in
patients with gastric cancer. Mutations in PIK3CA exons
9 and 20 were observed in 25 of the 208 (12 %) gastric
cancer patients. However, overall survival and disease-
free survival were similar in patients with and without
PIK3CA mutations, indicating that PIK3CA mutations
do not affect mortality after resection of gastric cancer.
PIK3CA exons 9 and 20 mutation accounted for over
the 80 % of the mutations [6]. Exon 9 mutation exist in
helical domain, and exon 20 mutation exist in kinase do-
main, leading to the activating of AKT pathway and then
stimulating the ability of invasion and migration [13].
Especially, E545K mutation disrupts inhibitory inter-
action between p110 and SH2 domain in p85 [21]. Im-
portantly, Baba et al. have shown the relationship
between tumor phosphorylated AKT expression and
PIK3CA exons 9 and 20 mutation in 717 colorectal can-
cer [22]. The oncogenic role of mutations other than hot
spot mutation has not been fully investigated. Interest-
ingly, some tumor samples had multiple mutations on
exon 9 and 20. Some group have also detected several
different PIK3CA mutations in same sample by using
next-generation sequencing and Sanger Sequencing. It is
possible that one sample harvest three or two different
mutations in the same gene [23, 24]. In addition,
PIK3CA mutation can coexist with KRAS, EGFR and
BRAF [25]. Thus, PIK3CA mutation has been involved
in molecular pathway of cancer.
Other studies have reported PIK3CA mutations in
4–25 % of gastric cancers (Table 2). The largest co-
hort was assessed by the TOGA study group, finding
that the PIK3CA mutation rate was 24 %, or about
twice as high as in the current study. However, that
study evaluated mutations in all exons. A study in a
Japanese population found that the mutation rate in
PIK3CA exons 1, 9, and 20, as determined by pyrose-
quencing, was 8.7 % [26]. Directed sequencing found
that the mutation rate in PIK3CA exons 9 and 20
was 7.7–15.9 % [27, 28]. Thus, the PIK3CA mutation
rate observed in the current study (12 %) was
comparable to rates previously reported. Interestingly,
the PIK3CA mutation rate in gastric cancer is less
than that in colon and breast cancers [29, 30].
Previous studies evaluating the association between
PIK3CA mutations and prognosis in human cancers
have yielded variable results (Table 3). PIK3CA muta-
tions have been associated with a better prognosis in
patients with breast and esophageal cancers, but with a
poorer prognosis in patients with colon, rectum, and
endometrial cancers [31–35]. These differences may be
due to differences in tumor histology. Discovering the
mechanisms of this discrepancy is imperative for future
projects.
The current study found that PIK3CA mutations were
not associated with survival in patients with gastric can-
cer, in agreement with three previous studies [26–28].
Because of their relatively large sample sizes, including
this study that included samples from over 200 samples,
these findings, taken together, confirm the lack of rela-
tionship between PIK3CA mutations and prognosis in
gastric cancer patients. These findings, however, require
confirmation by large independent cohort studies.
Conclusions
In conclusion, mutations in PIK3CA exons 9 and 20
were observed in 25 of the 208 (12 %) gastric cancer pa-
tients by pyrosequencing assays. We found that PIK3CA
mutations did not correlate with prognosis in patients
with gastric cancer, providing additional evidence for the
lack of relationship between the two.
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